Liraglutide alleviated Alpha-pyrrolidinovalerophenone (α-PVP) induced Cognitive deficits in rats by modifying brain mitochondrial impairment.

Alpha-pyrrolidinovalerophenone (α-PVP) Glucagon-like peptide 1 (GLP-1) agonist Liraglutide Memory impairment synthetic stimulant

Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
25 Jun 2024
Historique:
received: 01 05 2024
revised: 24 06 2024
accepted: 24 06 2024
medline: 28 6 2024
pubmed: 28 6 2024
entrez: 27 6 2024
Statut: aheadofprint

Résumé

The use of NPS compounds is increasing, and impairment in spatial learning and memory is a growing concern. Alpha-pyrrolidinovalerophenone (α-PVP) consumption, as a commonly used NPS, can impair spatial learning and memory through brain mitochondrial dysfunction mechanisem. Liraglutide, one of the most well-known Glucagon-like peptide 1 (GLP-1) agonist used as an anti-diabetic and anti-obesity drug. According to current research, Liraglutide likely ameliorate cognitive impairment in neurodegenerative conditions and also substance use disorders. Hence, the purpose of this study is examining the effect of Liraglutide on α-PVP induced spatial learning and memory problems due to brain mitochondrial dysfunction. Wistar rats (8 in each group) received α-PVP (20 mg/kg/d for 10 consecutive days, intraperitoneally (I.P.)). Then, Liraglutide was administered at 47 and 94 μg/kg/d, I.P., for 4 weeks following the α-PVP administration. The Morris Water Maze (MWM) task evaluated spatial learning and memory 24 hours after Liraglutide treatment. Bedside, brain mitochondrial activity parameters including reactive oxygen species (ROS) level, mitochondrial membrane potential (MMP), cytochrome c release, mitochondrial outer membrane damage and swelling, and brain ADP/ATP ratio were studied. Our results showed Liraglutide ameliorated α-PVP induced spatial learning and memory impairments through alleviating brain mitochondrial dysfunctions (which is indicated by increasing ROS formation, collapsed MMP, mitochondrial outer membrane damage, cytochrome c release, mitochondrial swelling, and brain ADP/ATP ratio) in rats. This study could be used as a starting point for future studies about the possible role of Liraglutide in mitochondrial dysfunction related to cognitive impairments due to substance use disorder.

Identifiants

pubmed: 38936451
pii: S0014-2999(24)00464-3
doi: 10.1016/j.ejphar.2024.176776
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

176776

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Auteurs

Marzieh Noruzi (M)

School of Pharmacy, Semnan University of Medical Sciences, Semnan, Iran.

Homayoon Behmadi (H)

School of Pharmacy, Semnan University of Medical Sciences, Semnan, Iran.

Omid Sabzevari (O)

Department of Toxicology & Pharmacology, Faculty of Pharmacy, and Toxicology & Poisoning Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

Alireza Foroumadi (A)

Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Hossein Ghahremani (MH)

School of Pharmacy, Semnan University of Medical Sciences, Semnan, Iran.

Jalal Pourahmad (J)

Department of Toxicology and Pharmacology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Shokoufeh Hassani (S)

Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, Iran.

Maryam Baeeri (M)

Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, Iran.

Mahdi Gholami (M)

Department of Toxicology & Pharmacology, Faculty of Pharmacy, Toxicology and Poisoning Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

Amirhosein Ghahremanian (A)

Department of Toxicology and Pharmacology, Faculty of Pharmacy, and Drug and Poision Information Centre, Tehran University of Medical Sciences, Tehran, Iran.

Soheila Seyfi (S)

Drug design and development research center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.

Ghorban Taghizadeh (G)

Rehabilitation Research Center, Department of Occupational Therapy, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran. Electronic address: taghizadeh.gh@iums.ac.ir.

Mohammad Sharifzadeh (M)

Department of Toxicology and Pharmacology, Faculty of Pharmacy, and The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran. Electronic address: msharifzadeh@tums.ac.ir.

Classifications MeSH